Ten years of dengue drug discovery: Progress and prospects

Siew Pheng Lim, Qing Yin Wang, Christian G. Noble, Yen Liang Chen, Hongping Dong, Bin Zou, Fumiaki Yokokawa, Shahul Nilar, Paul Smith, David Beer, Julien Lescar, Pei Yong Shi

Research output: Contribution to journalReview article

222 Scopus citations

Abstract

To combat neglected diseases, the Novartis Institute of Tropical Diseases (NITD) was founded in 2002 through private-public funding from Novartis and the Singapore Economic Development Board. One of NITD's missions is to develop antivirals for dengue virus (DENV), the most prevalent mosquito-borne viral pathogen. Neither vaccine nor antiviral is currently available for DENV. Here we review the progress in dengue drug discovery made at NITD as well as the major discoveries made by academia and other companies. Four strategies have been pursued to identify inhibitors of DENV through targeting both viral and host proteins: (i) HTS (high-throughput screening) using virus replication assays; (ii) HTS using viral enzyme assays; (iii) structure-based in silico docking and rational design; (iv) repurposing hepatitis C virus inhibitors for DENV. Along the developmental process from hit finding to clinical candidate, many inhibitors did not advance beyond the stage of hit-to-lead optimization, due to their poor selectivity, physiochemical or pharmacokinetic properties. Only a few compounds showed efficacy in the AG129 DENV mouse model. Two nucleoside analogs, NITD-008 and Balapiravir, entered preclinical animal safety study and clinic trial, but both were terminated due to toxicity and lack of potency, respectively. Celgosivir, a host alpha-glucosidase inhibitor, is currently under clinical trial; its clinical efficacy remains to be determined. The knowledge accumulated during the past decade has provided a better rationale for ongoing dengue drug discovery. Though challenging, we are optimistic that this continuous, concerted effort will lead to an effective dengue therapy.

Original languageEnglish (US)
Pages (from-to)500-519
Number of pages20
JournalAntiviral research
Volume100
Issue number2
DOIs
StatePublished - Oct 21 2013
Externally publishedYes

Keywords

  • Antiviral
  • Dengue virus
  • Drug discovery
  • Flavivirus

ASJC Scopus subject areas

  • Pharmacology
  • Virology

Fingerprint Dive into the research topics of 'Ten years of dengue drug discovery: Progress and prospects'. Together they form a unique fingerprint.

  • Cite this

    Lim, S. P., Wang, Q. Y., Noble, C. G., Chen, Y. L., Dong, H., Zou, B., Yokokawa, F., Nilar, S., Smith, P., Beer, D., Lescar, J., & Shi, P. Y. (2013). Ten years of dengue drug discovery: Progress and prospects. Antiviral research, 100(2), 500-519. https://doi.org/10.1016/j.antiviral.2013.09.013